Minimally invasive versus open McKeown esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant PD-1 inhibitor plus chemotherapy

Qiuming Chen, Shaocong Mo, Aizemaiti Rusidanmu, Jun Cheng, Ziheng Wu, Peng YeFrontiers in Oncology 2023 · DOI

TL;DR

This study compares minimally invasive (MIE) versus open McKeown esophagectomy in patients with esophageal squamous cell carcinoma (ESCC) who received neoadjuvant PD-1 inhibitor plus chemotherapy. The findings suggest that MIE is a safe and feasible option, demonstrating comparable survival outcomes to open surgery with potential benefits like shorter operative times.

What Problem Does This Paper Address?

Esophageal cancer, particularly ESCC, is a significant global health challenge, with most cases diagnosed at locally advanced stages. While surgery is a primary treatment, recurrence rates remain high. Neoadjuvant therapy, including chemotherapy and more recently immunotherapy (PD-1 inhibitors), has shown promise in improving outcomes. However, the combination of neoadjuvant immunotherapy with chemotherapy can lead to tissue edema and adhesions, potentially complicating surgical dissection. This raises a critical question: is minimally invasive McKeown esophagectomy (MIE) a safe and effective approach for these patients, or does the complexity introduced by neoadjuvant therapy favor traditional open surgery? This paper aims to address this by comparing the short- and mid-term outcomes of MIE versus open esophagectomy in this specific patient population.

Methods

This retrospective study analyzed data from 35 patients with locally advanced ESCC who underwent neoadjuvant camrelizumab (a PD-1 inhibitor) plus chemotherapy followed by either open or minimally invasive McKeown esophagectomy. The study collected and compared baseline characteristics, pathological data, and short- and mid-term outcomes between the two surgical groups.

Key methodological aspects include:

  • Neoadjuvant Treatment: Patients received at least two cycles of camrelizumab (200 mg) on day 1 and either nanoparticle albumin-bound paclitaxel (260 mg/m²) or cisplatin/carboplatin on day 2, every 21 days.
  • Surgical Procedures:
    • Open McKeown Esophagectomy: Involved right posterolateral thoracotomy, upper midline laparotomy, and cervical anastomosis.
  • Minimally Invasive McKeown Esophagectomy (MIE): Utilized right thoracoscopy with four ports, followed by laparoscopic gastric mobilization and upper abdominal lymph node dissection, and finally cervical anastomosis.
  • Outcome Assessment: Short-term outcomes included operative time, lymph node retrieval, and postoperative complications. Mid-term outcomes focused on recurrence rates, overall survival (OS), and disease-free survival (DFS). Pathological assessment included tumor regression grade (TRG) and response rates (PCR, MPR).
  • Statistical Analysis: Standard statistical methods were employed, including chi-square tests, Fisher's exact tests, and Kaplan-Meier analysis for survival curves.

Datasets

Not discussed in the paper. The study utilized retrospective data from patients treated at The First Affiliated Hospital of Zhejiang University School of Medicine.

Key Insights and Ideas

  • MIE is Feasible Post-Immunochemotherapy: The study demonstrates that MIE can be safely performed in patients who have received neoadjuvant PD-1 inhibitor plus chemotherapy, challenging concerns about increased surgical complexity.
  • Shorter Operative Times with MIE: MIE was associated with significantly shorter operative times compared to open surgery, a common benefit of minimally invasive approaches.
  • Comparable Survival Outcomes: Crucially, there were no significant differences in overall survival or disease-free survival between the MIE and open surgery groups, suggesting MIE does not compromise long-term oncological outcomes in this setting.
  • No Increased Surgical Complications: Despite the neoadjuvant therapy, the rates of postoperative complications were similar between the two groups, indicating that the treatment did not unduly increase surgical risks.
  • Potential for Improved Lymph Node Dissection in Open Surgery: While overall lymph node retrieval was similar, the open surgery group harvested more left recurrent laryngeal lymph nodes, suggesting potential advantages for systematic dissection in this specific area with open procedures.

Key Results

  • Patient Cohort: 35 patients were included, with 13 (37.1%) undergoing open surgery and 22 (62.9%) undergoing MIE.
  • Operative Time: MIE group had significantly shorter operative times (277.9 ± 30.2 min) compared to the open group (350.8 ± 117.8 min, P = 0.009).
  • Lymph Node Retrieval: No significant difference in total resected lymph nodes, but the open group harvested more left recurrent laryngeal lymph nodes (2.6 ± 3.2 vs. 0.9 ± 1.7, P = 0.047).
  • Survival:
    • Median follow-up: 1.42 years.
  • 2-year cumulative survival rates: 92.3 ± 7.4% (open) vs. 89.5 ± 7.1% (MIE).
  • Overall survival and disease-free survival were not significantly different between the groups.
  • Pathological Response: 11.4% of patients achieved pathological complete response (PCR), and 17.1% achieved major pathological response (MPR).
  • Postoperative Complications: 45.7% of patients developed complications, with no significant difference between groups. Left pleural effusion was the most common. No in-hospital mortality was observed.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Design: This inherently carries the risk of bias, as patients were not randomly assigned to surgical approaches but rather based on surgeon preference.
  • Small Sample Size: The study included only 35 patients, which limits the statistical power for detecting subtle differences.
  • Short Follow-up Time: While mid-term outcomes were assessed, longer-term follow-up is needed to fully evaluate the impact of neoadjuvant therapy and surgical approach on survival.

Future work should focus on larger, prospective, randomized controlled trials to confirm these findings and further investigate the optimal treatment regimens and long-term outcomes. The study also suggests that further research into systematic lymphadenectomy techniques for MIE, particularly around the recurrent laryngeal nerve, could be beneficial.

Summary updated

Abstract

MIE might be safe and feasible for patients with locally advanced ESCC undergoing neoadjuvant PD-1 inhibitor plus chemotherapy.
BibTeX
@inproceedings{chen2023minimally,
  author = {Qiuming Chen and Shaocong Mo and Aizemaiti Rusidanmu and Jun Cheng and Ziheng Wu and Peng Ye},
  title = {{Minimally invasive versus open McKeown esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant PD-1 inhibitor plus chemotherapy}},
  booktitle = {Frontiers in Oncology},
  year = {2023},
  doi = {10.3389/fonc.2023.1103421},
}
Figure